Correction to: Rheumatology and Therapy https://doi.org/10.1007/s40744-022-00498-x


In this article the legend for Fig. 5 was inadvertently with error, the legend for Fig. 5 should have appeared as shown below.

Fig. 5 LS mean CFB in mTSS among patients with any of the PPFs or four PPFs at A W24 or B W52. Each of the PPF subgroups [sero (+), hsCRP ≥ 6, DAS28(CRP) > 5.1, and erosion > 0] could include patients who also had other PPFs. *P < 0.05 versus PBO at W24; **P < 0.05 versus ADA at W52. Comparison to ADA at W24 is out of scope for statistical calculation. All treatment groups also received methotrexate. ADA adalimumab, CFB change from baseline, DAS28(CRP) disease activity score for rheumatoid arthritis in 28 joints with C-reactive protein, FIL100 filgotinib 100 mg, FIL200 filgotinib 200 mg, hsCRP high-sensitivity C-reactive protein, LS least squares, mTSS modified total Sharp score, PBO placebo, PPF poor prognostic factor, Sero (+) seropositivity for rheumatoid factor or anti-yclic citrullinated peptide, W week.

The original article is updated accordingly.